dc.contributor.author |
Englisch, Alexander |
|
dc.contributor.author |
Hayn, Clara |
|
dc.contributor.author |
Jung, Susanne |
|
dc.contributor.author |
Heitmann, Jonas S. |
|
dc.contributor.author |
Hackenbruch, Christopher |
|
dc.contributor.author |
Maringer, Yacine |
|
dc.contributor.author |
Nelde, Annika |
|
dc.contributor.author |
Wacker, Marcel |
|
dc.contributor.author |
Denk, Monika |
|
dc.contributor.author |
Zieschang, Lisa |
|
dc.contributor.author |
Kammer, Christine |
|
dc.contributor.author |
Martus, Peter |
|
dc.contributor.author |
Salih, Helmut R. |
|
dc.contributor.author |
Walz, Juliane S. |
|
dc.date.accessioned |
2025-01-28T07:42:59Z |
|
dc.date.available |
2025-01-28T07:42:59Z |
|
dc.date.issued |
2024 |
|
dc.identifier.issn |
2234-943X |
|
dc.identifier.uri |
http://hdl.handle.net/10900/161226 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Lausanne : Frontiers Media Sa |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.3389/fonc.2024.1441625 |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20241001000000_00265 |
|
utue.personen.roh |
Englisch, Alexander |
|
utue.personen.roh |
Hayn, Clara |
|
utue.personen.roh |
Jung, Susanne |
|
utue.personen.roh |
Heitmann, Jonas S. |
|
utue.personen.roh |
Hackenbruch, Christopher |
|
utue.personen.roh |
Maringer, Yacine |
|
utue.personen.roh |
Nelde, Annika |
|
utue.personen.roh |
Wacker, Marcel |
|
utue.personen.roh |
Denk, Monika |
|
utue.personen.roh |
Zieschang, Lisa |
|
utue.personen.roh |
Kammer, Christine |
|
utue.personen.roh |
Martus, Peter |
|
utue.personen.roh |
Salih, Helmut R. |
|
utue.personen.roh |
Walz, Juliane S. |
|
dcterms.isPartOf.ZSTitelID |
Frontiers in Oncology |
de_DE |
dcterms.isPartOf.ZS-Issue |
Article 1441625 |
de_DE |
dcterms.isPartOf.ZS-Volume |
14 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |